Physician profile
Scott E Eggener
NPI 1548440027
$64,248.09
in general payments reported to CMS, 2019-2025
12 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $7,750 · 2021: $2,366 · 2022: $11K · 2023: $6,103 · 2024: $2,246 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,993 · Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,993.00 |
| Food and Beverage | $684.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28,292.55 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Janssen Scientific Affairs, LLC | $12,411.73 | 2019-2023 | |
| Insightec,INC | $9,269.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $5,474.39 | 2019 | |
| Progenics Pharmaceuticals, INC. | $4,438.00 | 2020-2023 | Pylarify |
| Janssen Global Services, LLC | $2,245.97 | 2024 | |
| Pfizer INC. | $1,050.00 | 2021 | |
| Insightec,Ltd | $816.28 | 2019 | |
| Boston Scientific Corporation | $125.49 | 2022 | |
| Profound Medical Corp. | $94.48 | 2022 | |
| Coloplast Corp | $29.45 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Eggener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.